Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors

Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

(2022) Brian A. Bergmark et al.   CIRCULATION

Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia

(2022) Ewa Karwatowska-Prokopczuk et al.   Journal of Clinical Lipidology

Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations

(2022) Marja-Riitta Taskinen et al.   JCI Insight

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

(2022) Aruna Das Pradhan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study

(2022) Yuji Nishizaki et al.   AMERICAN HEART JOURNAL

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2021) Ioanna Gouni-Berthold et al.   Lancet Diabetes & Endocrinology

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk

(2021) Steven E. Nissen et al.   JAMA Cardiology

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

(2021) Henry N Ginsberg et al.   EUROPEAN HEART JOURNAL

Volanesorsen for treatment of familial chylomicronemia syndrome

(2021) Julieta Lazarte et al.   Expert Review of Cardiovascular Therapy

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

(2021) Jean-Claude Tardif et al.   EUROPEAN HEART JOURNAL

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

(2020) Daniel Gaudet et al.   EUROPEAN HEART JOURNAL

Evinacumab for Homozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

(2020) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia

(2019) Ya-Bin Ma et al.   EXPERT OPINION ON PHARMACOTHERAPY

Cholesterol-Lowering Agents

(2019) Robert S. Rosenson et al.   CIRCULATION RESEARCH

ApoC-III ASO Promotes Tissue LPL Activity in Absence of ApoE-Mediated TRL Clearance

(2019) Bastian Ramms et al.   JOURNAL OF LIPID RESEARCH

Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes

(2019) Jenny E. Kanter et al.   JOURNAL OF CLINICAL INVESTIGATION

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

(2019) Joseph L. Witztum et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism

(2018) Bastian Ramms et al.   CURRENT OPINION IN LIPIDOLOGY

The Evolving Future of PCSK9 Inhibitors

(2018) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism

(2018) Gissette Reyes-Soffer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

(2018) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity

(2017) Danish Saleheen et al.   NATURE

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes

(2017) Marshall B. Elam et al.   JAMA Cardiology

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

(2016) Andres Digenio et al.   DIABETES CARE

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors

(2016) Philip L.S.M. Gordts et al.   JOURNAL OF CLINICAL INVESTIGATION

Ezetimibe plus simvastatin for the treatment of hypercholesterolemia

(2015) Steven E Gryn et al.   EXPERT OPINION ON PHARMACOTHERAPY

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

(2015) Daniel Gaudet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rare Variant APOC3 R19X Is Associated With Cardio-Protective Profiles in a Diverse Population-Based Survey as Part of the Epidemiologic Architecture for Genes Linked to Environment Study

(2014) D. C. Crawford et al.   Circulation-Cardiovascular Genetics

Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease

(2014) Anders Berg Jørgensen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting APOC3 in the Familial Chylomicronemia Syndrome

(2014) Daniel Gaudet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Apolipoprotein C-III

(2013) Murray W. Huff et al.   CIRCULATION RESEARCH

A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection

(2008) T. I. Pollin et al.   SCIENCE